Verubecestat
Verubecestat is an experimental drug developed for the treatment of Alzheimer's disease. It is a BACE1 inhibitor, which means it works by blocking the action of an enzyme called beta-secretase 1 that is involved in the production of a protein called beta-amyloid. Beta-amyloid is a key component of the plaques that form in the brains of people with Alzheimer's disease.
Development and Clinical Trials
Verubecestat was developed by Merck & Co., a multinational pharmaceutical company. The drug entered Phase III clinical trials in 2015, making it the first BACE1 inhibitor to reach this stage of development. However, in 2018, Merck announced that it was discontinuing these trials because an interim analysis showed that the drug was unlikely to show a positive benefit-risk ratio.
The failure of Verubecestat in clinical trials was a significant setback for the development of BACE1 inhibitors as a treatment for Alzheimer's disease. However, it also provided valuable information about the role of beta-amyloid in the disease and the potential risks and benefits of targeting this protein.
Mechanism of Action
Verubecestat works by inhibiting the action of BACE1, an enzyme that plays a key role in the production of beta-amyloid. By blocking this enzyme, the drug reduces the levels of beta-amyloid in the brain. This is thought to slow the progression of Alzheimer's disease by preventing the formation of plaques.
However, the clinical trials of Verubecestat showed that this approach may not be effective. This has led to a re-evaluation of the role of beta-amyloid in Alzheimer's disease and the potential benefits of targeting this protein.
Future Research
Despite the failure of Verubecestat in clinical trials, research into BACE1 inhibitors and other approaches to reducing beta-amyloid levels continues. It is hoped that this research will lead to the development of more effective treatments for Alzheimer's disease in the future.
| Alzheimer's disease topics | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This Alzheimer's disease related article is a stub.
|
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
